Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CETP | P11597 | 19/20 | 0.67 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.51 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.51 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9885322 | 0.88 | CETP (0.70) | CETPTBXA2RPTGDRPTGDR2 | |
| SCHEMBL9885316 | 0.87 | CETP (0.68) | CETPTBXA2RPTGDRPTGDR2 | |
| SCHEMBL3559191 | 0.86 | GPBAR1 (0.54) | CETP | |
| SCHEMBL3551798 | 0.85 | CETP (0.49) | CETPTBXA2RPTGDRPTGDR2 | |
| SCHEMBL3553339 | 0.85 | CETP (0.66) | CETPTBXA2RPTGDRPTGDR2 | |
| SCHEMBL3554373 | 0.84 | CETP (0.64) | CETPTBXA2RPTGDRPTGDR2 | |
| SCHEMBL12664976 | 0.82 | CETP (0.65) | CETPTBXA2RPTGDRPTGDR2 | |
| SCHEMBL1897565 | 0.82 | CETP (0.63) | CETPTBXA2RPTGDRPTGDR2 | |
| SCHEMBL13312983 | 0.81 | CETP (0.62) | CETPTBXA2RPTGDRPTGDR2 | |
| SCHEMBL1896128 | 0.79 | CETP (0.59) | CETPTBXA2RPTGDRPTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1737811-B1 | CETP INHIBITORS | MERCK SHARP & DOHME (US) | 2016-08-10 | — | — | EP | disclosed |
| US-8193365-B2 | CETP inhibitors | MERCK SHARP & DOHME CORP. (US) | 2012-06-05 | — | — | US | disclosed |
| US-8193365-B2 | CETP inhibitors | MERCK SHARP & DOHME CORP. (US) | 2012-06-05 | — | — | US | disclosed |
| US-8193365-B2 | CETP inhibitors | MERCK SHARP & DOHME CORP. (US) | 2012-06-05 | — | — | US | disclosed |
| US-7935727-B2 | CETP inhibitors | MERCK SHARP & DOHME CORP. (US) | 2011-05-03 | — | — | US | disclosed |
| US-20100249024-A1 | CETP INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2010-09-30 | — | — | US | disclosed |
| US-20100249024-A1 | CETP INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2010-09-30 | — | — | US | disclosed |
| US-20100249024-A1 | CETP INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2010-09-30 | — | — | US | disclosed |
| US-7737295-B2 | CETP inhibitors | MERCK SHARP & DOHME CORP. (US) | 2010-06-15 | — | — | US | disclosed |
| US-7737295-B2 | CETP inhibitors | MERCK SHARP & DOHME CORP. (US) | 2010-06-15 | — | — | US | disclosed |
| US-20090124689-A1 | CETP Inhibitors | MERCK SHARP & DOHME CORP. | 2009-05-14 | — | — | US | disclosed |
| US-20070225365-A1 | Cetp Inhibitors | MERCK & CO., INC. (US) | 2007-09-27 | — | — | US | disclosed |
| US-20070225365-A1 | Cetp Inhibitors | MERCK & CO., INC. (US) | 2007-09-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225365-A1 | Cetp Inhibitors | CETP, APOB, NPC1 | CETP 1/4885TBXA2R 579/4885PTGDR 4663/4885 |
| US-20100249024-A1 | CETP INHIBITORS | CETP, APOB, NPC1 | CETP 1/4885TBXA2R 579/4885PTGDR 4663/4885 |
| US-20090124689-A1 | CETP Inhibitors | CETP, APOB, MTTP | CETP 1/4885TBXA2R 1082/4885PTGDR 4730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.